Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.47 |
| ▸ | WNT1 | P04628 | 3/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | CLK3 | P49761 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27197026 | 0.92 | ABL1 (0.50) | ABL1 | |
| SCHEMBL27196990 | 0.90 | ABL1 (0.50) | ABL1 | |
| SCHEMBL27197253 | 0.90 | ABL1 (0.49) | ABL1 | |
| SCHEMBL27197104 | 0.84 | DYRK1A (0.52) | ABL1DYRK1AGSK3BWNT1 | |
| SCHEMBL29776474 | 0.84 | DYRK1A (0.52) | ABL1DYRK1AGSK3BWNT1 | |
| SCHEMBL29776336 | 0.81 | MAPK1 (0.42) | MAPK14MAPK1 | |
| SCHEMBL27197214 | 0.81 | MAPK1 (0.42) | MAPK14MAPK1 | |
| SCHEMBL27197013 | 0.79 | ABL1 (0.50) | ABL1DYRK1AGSK3BWNT1 | |
| SCHEMBL29094420 | 0.79 | NOTUM (0.39) | ABL1DYRK1AGSK3BMAPK1 | |
| SCHEMBL24605603 | 0.77 | ABL1 (0.55) | ABL1DYRK1AGSK3BWNT1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | claimed |
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | claimed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | claimed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | claimed |
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CYP11B2, CYP11B1, CYP8B1 | ABL1 1664/4885DYRK1A 1850/4885GSK3B 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.